Bristol Myers Squibb's Cobenfy Clinical Trial Shows Positive Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy BMY?
Source: Newsfilter
- Clinical Trial Results: Bristol Myers Squibb's Cobenfy demonstrated stability in 105 schizophrenia patients over an 8-week Phase 4 trial, with mean PANSS scores remaining below baseline regardless of cross-titration strategy, indicating its efficacy and safety in treatment.
- High Patient Completion Rate: Approximately 86% of patients completed the 8-week treatment, with discontinuation rates of 15.1% in the slower and 13.5% in the faster transition groups, and no patients discontinued due to lack of efficacy, showcasing Cobenfy's good tolerability.
- Significant Symptom Improvement: The mean change in PANSS total scores was -4.2 for the slower transition group and -3.1 for the faster group, with both groups showing a CGI-S score change of -0.2, indicating notable symptom improvement and supporting Cobenfy's clinical application potential.
- Innovative Treatment Mechanism: As the first novel mechanism for schizophrenia treatment in decades, Cobenfy provides crucial clinical data that aids physicians in making informed decisions during patient treatment transitions, advancing progress in mental health care.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to fall
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 59.430
Low
37.00
Averages
55.86
High
68.00
Current: 59.430
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bristol Myers Squibb's Cobenfy Clinical Trial Shows Positive Results
- Clinical Trial Results: Bristol Myers Squibb's Cobenfy demonstrated stability in 105 schizophrenia patients over an 8-week Phase 4 trial, with mean PANSS scores remaining below baseline regardless of cross-titration strategy, indicating its efficacy and safety in treatment.
- High Patient Completion Rate: Approximately 86% of patients completed the 8-week treatment, with discontinuation rates of 15.1% in the slower and 13.5% in the faster transition groups, and no patients discontinued due to lack of efficacy, showcasing Cobenfy's good tolerability.
- Significant Symptom Improvement: The mean change in PANSS total scores was -4.2 for the slower transition group and -3.1 for the faster group, with both groups showing a CGI-S score change of -0.2, indicating notable symptom improvement and supporting Cobenfy's clinical application potential.
- Innovative Treatment Mechanism: As the first novel mechanism for schizophrenia treatment in decades, Cobenfy provides crucial clinical data that aids physicians in making informed decisions during patient treatment transitions, advancing progress in mental health care.
See More
CNBC Investing Club March Meeting Overview
- Energy Stocks Surge: Following the outbreak of war in Iran, energy stocks, particularly fertilizer manufacturers, have shown strong performance, indicating robust market demand that could drive profitability for related companies.
- AWS Growth Acceleration: Amazon's cloud unit AWS is no longer lagging behind Microsoft Azure, thanks to its partnership with Anthropic, with expectations for next quarter's margins to exceed market forecasts, boosting investor confidence.
- Cybersecurity Challenges: CrowdStrike has been affected by turmoil in the software market, but the CEO highlighted the positive impact of AI on cyberattacks, indicating long-term growth potential in the security sector, despite high stock prices.
- Healthcare Sector Risks: Eli Lilly faces pricing pressure from competitor Novo Nordisk, but the company is prepared to counter this by increasing volume, with the upcoming launch of its GLP-1 obesity drug expected to drive growth.
See More
US Stocks Rise on Easing US-Iran Tensions
- Easing US-Iran Relations: The US proposed a 15-point peace plan to Iran, facing some resistance, yet the optimism surrounding this development has led to a rise in US stocks, indicating a positive investor response to reduced geopolitical risks.
- Oil Price Fluctuations: Global benchmark Brent crude fell to around $102 per barrel, reflecting concerns over supply surplus, while bond yields also dropped, suggesting an increased investor preference for risk assets amid easing tensions.
- Boeing Order Expectations: President Trump is set to meet Chinese President Xi Jinping in May, with expectations of announcing Boeing's first major order from China in nearly a decade, which could positively impact Boeing's market outlook and enhance its competitiveness in the Chinese market.
- Honeywell Investment: Honeywell signed a
See More
AbbVie and Bristol Myers Squibb's Dividend Performance
- AbbVie's Dividend King Status: AbbVie is not only a reliable dividend raiser but also a Dividend King, having increased its dividend for 50 consecutive years; despite facing the patent expiration of Humira, management strategically bolstered its pipeline with Skyrizi and Rinvoq, which generated $7.4 billion in net revenue in Q4, accounting for 44% of total revenue.
- Strong Cash Flow Support: AbbVie's robust free cash flow is more than sufficient to sustain its quarterly dividend of $1.73 per share, currently yielding 3.4%, ensuring the company's ability to maintain dividend stability and attractiveness amid market fluctuations.
- Bristol Myers Squibb's Innovative Response: Facing similar patent cliff challenges, particularly with cancer drugs, Bristol Myers Squibb's growth portfolio achieved a 16% year-over-year revenue increase in Q4, nearing $7.4 billion, demonstrating the company's resilience in navigating market pressures.
- Solid Financial Forecast: Despite a 15% decline in revenue from its legacy portfolio to $5.1 billion, Bristol Myers Squibb's management projects annual revenue between $46 billion and $47.5 billion for 2023, with free cash flow at $12.8 billion, significantly exceeding the $5 billion needed for dividends, ensuring a sustainable dividend yield of 4.4%.
See More
Dividend Performance of AbbVie and Bristol Myers Squibb
- AbbVie's Dividend King Status: AbbVie is not only a reliable dividend raiser but also a Dividend King, having increased its dividend annually for 50 years, and despite facing the patent expiration of Humira, its management has effectively navigated challenges through strategic acquisitions and new drug development, ensuring strong cash flow and a quarterly dividend of $1.73 per share, currently yielding 3.4%.
- New Drug Revenue Growth: AbbVie's next-generation drugs, Skyrizi and Rinvoq, generated a combined net revenue of $7.4 billion in the fourth quarter, accounting for 44% of the company's total revenue, demonstrating its strong market adaptability post-Humira patent loss and further solidifying its leadership in the biopharmaceutical sector.
- Bristol Myers Squibb's Innovative Response: Facing patent cliffs with cancer drugs like Revlimid and Opdivo, Bristol Myers Squibb has driven growth through innovation, with its growth portfolio's revenue increasing by 16% year-over-year to nearly $7.4 billion in the fourth quarter, alleviating the revenue decline from its legacy portfolio and showcasing resilience in adversity.
- Strong Free Cash Flow: Although Bristol Myers Squibb may experience a decline in free cash flow, which was $12.8 billion last year, significantly exceeding the $5 billion needed for dividend payments, its current dividend yield stands at 4.4%, providing a stable return outlook for long-term investors.
See More
Abraxane and Anktiva Combination Therapy Advances
- Combination Therapy Potential: Founder Patrick Soon-Shiong indicated that combining Abraxane with ImmunityBio's Anktiva could enhance immune responses by 'exposing' tumors and boosting macrophage activity, thereby improving treatment outcomes, particularly in pancreatic cancer patients.
- Clinical Trial Progress: The latest Phase 1 trial demonstrates that Anktiva, in conjunction with Abraxane and other agents, is being evaluated for safety and efficacy in patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma, potentially offering new pre-surgical treatment options.
- Market Recognition Boost: Anktiva's recent inclusion in Macau's approved drug list and endorsement by the National Comprehensive Cancer Network (NCCN) as a recommended treatment for bladder cancer further solidifies its market position and expands its therapeutic applications.
- Investor Sentiment Shift: Despite IBRX shares surging nearly 250% over the past year, recent retail sentiment on Stocktwits has turned 'bearish', indicating a cautious outlook among investors regarding the stock's future performance, reflecting a divergence in perceptions of its potential.
See More
Bristol Myers Squibb's Cobenfy Clinical Trial Shows Positive Results
- Clinical Trial Results: Bristol Myers Squibb's Cobenfy demonstrated stability in 105 schizophrenia patients over an 8-week Phase 4 trial, with mean PANSS scores remaining below baseline regardless of cross-titration strategy, indicating its efficacy and safety in treatment.
- High Patient Completion Rate: Approximately 86% of patients completed the 8-week treatment, with discontinuation rates of 15.1% in the slower and 13.5% in the faster transition groups, and no patients discontinued due to lack of efficacy, showcasing Cobenfy's good tolerability.
- Significant Symptom Improvement: The mean change in PANSS total scores was -4.2 for the slower transition group and -3.1 for the faster group, with both groups showing a CGI-S score change of -0.2, indicating notable symptom improvement and supporting Cobenfy's clinical application potential.
- Innovative Treatment Mechanism: As the first novel mechanism for schizophrenia treatment in decades, Cobenfy provides crucial clinical data that aids physicians in making informed decisions during patient treatment transitions, advancing progress in mental health care.
See More
CNBC Investing Club March Meeting Overview
- Energy Stocks Surge: Following the outbreak of war in Iran, energy stocks, particularly fertilizer manufacturers, have shown strong performance, indicating robust market demand that could drive profitability for related companies.
- AWS Growth Acceleration: Amazon's cloud unit AWS is no longer lagging behind Microsoft Azure, thanks to its partnership with Anthropic, with expectations for next quarter's margins to exceed market forecasts, boosting investor confidence.
- Cybersecurity Challenges: CrowdStrike has been affected by turmoil in the software market, but the CEO highlighted the positive impact of AI on cyberattacks, indicating long-term growth potential in the security sector, despite high stock prices.
- Healthcare Sector Risks: Eli Lilly faces pricing pressure from competitor Novo Nordisk, but the company is prepared to counter this by increasing volume, with the upcoming launch of its GLP-1 obesity drug expected to drive growth.
See More
US Stocks Rise on Easing US-Iran Tensions
- Easing US-Iran Relations: The US proposed a 15-point peace plan to Iran, facing some resistance, yet the optimism surrounding this development has led to a rise in US stocks, indicating a positive investor response to reduced geopolitical risks.
- Oil Price Fluctuations: Global benchmark Brent crude fell to around $102 per barrel, reflecting concerns over supply surplus, while bond yields also dropped, suggesting an increased investor preference for risk assets amid easing tensions.
- Boeing Order Expectations: President Trump is set to meet Chinese President Xi Jinping in May, with expectations of announcing Boeing's first major order from China in nearly a decade, which could positively impact Boeing's market outlook and enhance its competitiveness in the Chinese market.
- Honeywell Investment: Honeywell signed a
See More
AbbVie and Bristol Myers Squibb's Dividend Performance
- AbbVie's Dividend King Status: AbbVie is not only a reliable dividend raiser but also a Dividend King, having increased its dividend for 50 consecutive years; despite facing the patent expiration of Humira, management strategically bolstered its pipeline with Skyrizi and Rinvoq, which generated $7.4 billion in net revenue in Q4, accounting for 44% of total revenue.
- Strong Cash Flow Support: AbbVie's robust free cash flow is more than sufficient to sustain its quarterly dividend of $1.73 per share, currently yielding 3.4%, ensuring the company's ability to maintain dividend stability and attractiveness amid market fluctuations.
- Bristol Myers Squibb's Innovative Response: Facing similar patent cliff challenges, particularly with cancer drugs, Bristol Myers Squibb's growth portfolio achieved a 16% year-over-year revenue increase in Q4, nearing $7.4 billion, demonstrating the company's resilience in navigating market pressures.
- Solid Financial Forecast: Despite a 15% decline in revenue from its legacy portfolio to $5.1 billion, Bristol Myers Squibb's management projects annual revenue between $46 billion and $47.5 billion for 2023, with free cash flow at $12.8 billion, significantly exceeding the $5 billion needed for dividends, ensuring a sustainable dividend yield of 4.4%.
See More
Dividend Performance of AbbVie and Bristol Myers Squibb
- AbbVie's Dividend King Status: AbbVie is not only a reliable dividend raiser but also a Dividend King, having increased its dividend annually for 50 years, and despite facing the patent expiration of Humira, its management has effectively navigated challenges through strategic acquisitions and new drug development, ensuring strong cash flow and a quarterly dividend of $1.73 per share, currently yielding 3.4%.
- New Drug Revenue Growth: AbbVie's next-generation drugs, Skyrizi and Rinvoq, generated a combined net revenue of $7.4 billion in the fourth quarter, accounting for 44% of the company's total revenue, demonstrating its strong market adaptability post-Humira patent loss and further solidifying its leadership in the biopharmaceutical sector.
- Bristol Myers Squibb's Innovative Response: Facing patent cliffs with cancer drugs like Revlimid and Opdivo, Bristol Myers Squibb has driven growth through innovation, with its growth portfolio's revenue increasing by 16% year-over-year to nearly $7.4 billion in the fourth quarter, alleviating the revenue decline from its legacy portfolio and showcasing resilience in adversity.
- Strong Free Cash Flow: Although Bristol Myers Squibb may experience a decline in free cash flow, which was $12.8 billion last year, significantly exceeding the $5 billion needed for dividend payments, its current dividend yield stands at 4.4%, providing a stable return outlook for long-term investors.
See More
Abraxane and Anktiva Combination Therapy Advances
- Combination Therapy Potential: Founder Patrick Soon-Shiong indicated that combining Abraxane with ImmunityBio's Anktiva could enhance immune responses by 'exposing' tumors and boosting macrophage activity, thereby improving treatment outcomes, particularly in pancreatic cancer patients.
- Clinical Trial Progress: The latest Phase 1 trial demonstrates that Anktiva, in conjunction with Abraxane and other agents, is being evaluated for safety and efficacy in patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma, potentially offering new pre-surgical treatment options.
- Market Recognition Boost: Anktiva's recent inclusion in Macau's approved drug list and endorsement by the National Comprehensive Cancer Network (NCCN) as a recommended treatment for bladder cancer further solidifies its market position and expands its therapeutic applications.
- Investor Sentiment Shift: Despite IBRX shares surging nearly 250% over the past year, recent retail sentiment on Stocktwits has turned 'bearish', indicating a cautious outlook among investors regarding the stock's future performance, reflecting a divergence in perceptions of its potential.
See More
